Daniél Vega Møller graduated in Medicine at the University of Copenhagen in 2000, where he also obtained his PhD within molecular cardio-genetics and heart failure. He has also been involved in the analysis of different biomarkers and their importance for prediction within the field of hypertension, CVD and obesity. After 10 years in the hospital setting in internal medicine, mainly cardiology, he moved to the pharma-industry and has been employed for more than 15 years focusing on drug development within the portfolio of insulin, obesity, liver health and metabolism, as well as Medial Affairs roles both at affiliate and regional level.

He is currently Vice President in the Strategic Operations of Novo Nordisk Health Care AG situated in the headquarter for international operations in Zürich, Switzerland. He is overall responsible for the Medical & Scientific Affairs activities focusing on cardiometabolic diseases like obesity, diabetes, cardio-vascular and chronic kidney diseases among others.

Marleen van der Voort holds an MD and a Diploma of Pharmaceutical Medicine, and built a career that combines scientific rigor, medical strategy, and global operational excellence.

With over 18 years of experience, her career spans local and global Medical Affairs roles across medical strategy, scientific communications, medical education, scientific exchange, and process excellence—enabling her to blend scientific depth with strategic leadership and systems thinking.

She currently serves as Global Head of Medical Engagement at Astellas, where she leads the development and implementation of global standards and processes for Field Medical, Medical Education, and Omnichannel Engagement to drive efficiency, effectiveness, and impact across Medical Affairs.

Previously, Marleen established the new Global Scientific Communications & Content group at Astellas, overseeing integrated evidence dissemination plans and delivery of central scientific content for local use which drives efficiency and enables a consistent scientific narrative.

Across her roles, Marleen has driven large‑scale organizational improvements, harmonized cross‑functional ways of working, and enabled medical teams worldwide through capability building and frameworks. She remains committed to enhancing scientific engagement and strengthening the role of Medical Affairs to close educational gaps to improve outcomes for patients.

Arnas is paediatrician with passion for vaccination and strong believe in prevention as a key intervention that can improve public health. 

He obtained his MD degree in Lithuania, Vilnius University, in 1996. Prior graduating, he also completed a clerkship in University of Wisconsin-Madison, USA. 

Dr Arnas Berzanskis has more than 27 years of experience in Pharmaceutical Industry. He has worked in multiple local, regional, global roles across a variety of business departments (medical, clinical, commercial) which allows him to have a strategic view of the industry. 

Arnas is currently supervising a team of talented scientists and entrepreneurs who are reshaping the medical landscape towards improved healthcare and prevention. 

His recent scientific publications in peer review journals focus on burden of RSV in adults. 

Dr. Elena Rizova, holding an M.D. and a Ph.D., boasts an impressive 25-year tenure in the biopharmaceutical sector, with a primary focus on international drug development. Her extensive experience spans from the early stages of clinical development to product launch. This rich background seamlessly blends clinical medicine and fundamental scientific research, with a geographical footprint encompassing Europe, the USA, Asia, Latin America, and the Middle East.

Until recently she serves as the Vice President and Head of Medical for the Biogen Intercontinental Region, a role she assumed in February 2021. This region encompasses Latin America, Australia, Asia, Japan, the Middle East, Turkey, and Russia.

Throughout her career, Dr. Rizova has honed her abilities in working with and leading multidisciplinary teams. Her expertise lies in integrating Research and Development, Medical Affairs, Clinical Operations, Regulatory Affairs, and Pharmacovigilance seamlessly.

Dr. Rizova's journey includes a series of senior leadership positions with escalating responsibilities. She commenced her career as a Medical Director at R&D Galderma and subsequently held various senior roles at Janssen (J&J) between 2007 and 2015. At J&J, she achieved remarkable milestones, notably as the Head of Immunology Franchise for Europe, where she led the launch of Stelara. She then ascended to the role of Head of Asia Pacific Medical Affairs, overseeing all franchises, and eventually became Head of External Innovation cross-sector at J&J.

In 2015, Dr. Rizova embarked on a new chapter, joining Sanofi Genzyme as the VP and Head of World Wide Medical Affairs Immunology, where she played a pivotal role in shaping the medical strategy for the global launch of Dupixent. After an impactful six-year tenure at Sanofi, she transitioned to Biogen as the Head of Biogen Intercontinental Region, responsible for the Medical Team across Asia, Latin America, and the Middle East, overseeing all Biogen franchises.

Dr. Rizova's academic credentials include an M.D. from the Academy of Medicine in Sofia, Bulgaria, a Ph.D. in Immunology, and a Diploma in Pharmacoeconomics from the University of Paris XI, France.

She brings to the table a diverse skill set, a profound commitment to innovation, and an unwavering dedication to personal and professional growth. Her forte lies in thriving in dynamic, collaborative environments, leveraging her exceptional communication and leadership skills to steer teams towards achieving collective objectives.

With more than 26 years of global experience at Eli Lilly, Vlado has led Medical Affairs organizations across the U.S. and international markets, advancing their evolution into customer-focused, business relevant science partners.

He has held senior leadership roles spanning multiple geographies and therapeutic areas, with responsibility for strategic direction, organizational leadership, evidence strategy, and product commercialization.

His expertise includes global therapeutic area and portfolio strategy, geographic and functional leadership, turning evidence into customer knowledge and clinical impact, and launch excellence.

He earned his M.D. from Comenius University and has clinical experience in both Slovakia and the United States.

Vlado currently serves as an external Senior Advisor to BCG, leveraging his experience to provide strategic guidance for their clients in life sciences.

Ron Weathermon, PharmD, is a seasoned Medical Affairs leader with more than 25 years of experience spanning global, regional, and local roles in the pharmaceutical industry. As Head of Innovation and Scientific Excellence at Teva Global Medical Affairs, he drives the development of forward-looking medical strategies, fosters cross-functional collaboration, and champions scientific innovation and governance across the organization. Prior to joining Teva, Ron served as Global Head of Medical Affairs Governance at Novartis, where he led large-scale organizational transformations, established a global governance framework, and expanded medical field capabilities. Recognized for his ability to align scientific excellence with business strategy, he has built and developed high-performing teams, enhanced medical compliance systems, and integrated medical functions across diverse therapeutic areas—advancing both innovation and operational rigor.

SSourav is currently the Head of Global Services, Medical and Scientific Affairs at Boehringer Ingelheim. He leads the Medical and Scientific Affairs Communication services hub in the Barcelona delivery unit, supporting our Medical Affairs teams in HQ and regions execute on their scientific communication priorities across Field and digital channels at scale. He has over 18 years of experience in the industry and has held medical engagement strategy and execution roles across Life Science companies driving capability building and change at scale in complex big pharma matrix environments.

Ana Amaral is the Customer Insights & Analytics Lead at Merck. Ana has held various roles within Regional and Global Medical Affairs and has experience developing and implementing strategies, operating models, and tools for Medical Information, HCP Engagement, Capability Building, Performance Management, Content Management, Medical Insights, Data Management, and Analytics. She holds a degree in Pharmacy and Biochemistry from the University of São Paulo and is currently an Executive MBA candidate at IESE Business School.

Mikko is Senior Director, Integrated Communications Strategy at Prime, a trusted, world-leading partner in life science communications, engagement and value optimization for the bio‑pharmaceutical industry. In his role, Mikko partners with pharma and biotech companies to design innovative strategic engagement programmes that drive clinical behaviour change, primarily under a Medical Affairs remit. He has worked across multiple therapy areas, with particular experience in oncology, rare diseases, and neurology, across Global, Regional, and Local levels – including a stint in Pfizer’s Rare Diseases business. Mikko holds an Executive MBA from Cranfield School of Management.

Caroline Phillips is Vice President of Medical Affairs at Medscape, with over 25 years of experience in the pharmaceutical industry. Medscape Medical Affairs specialises in the translation of clinical science through effective medical communications to enhance patient care. With a background in pharma, medical publishing and CME, Caroline brings a broad perspective to conversations in medical affairs and a strong desire to optimise effectiveness in medical education, delivering programs that are guaranteed to engage the right HCP targets, with measurable impact. 

With a career spanning both digital and traditional landscapes, Scott is known for his ability to translate complex business challenges into impactful, high-value solutions. As part of the team at Springer Health+, he brings extensive experience in navigating the intersection of strategic innovation and the evolving life sciences landscape.

Scott’s background is characterised by a holistic approach to the industry, having worked across diverse functions including Medical Devices, Medical Affairs, Medical Information, Brand, and Market Access. His expertise lies in developing and executing comprehensive strategies that align with broader business goals. This strategic focus is complemented by his experience in overseeing the development of AI-powered literature surveillance and PV platforms, as well as providing sophisticated multi-platform data visualisation solutions designed to drive deeper engagement with healthcare professionals.

Whether collaborating with global pharmaceutical leaders on product launches or developing patient-focused initiatives, Scott is dedicated to leveraging innovation to improve efficiency and health outcomes. His work is defined by a meticulous, strategic mindset that ensures digital and traditional channels work in harmony to meet the evolving needs of all stakeholders.

Marcel Beswick is Director of Data Analytics at Medscape Global. Medscape Medical Affairs specialises in the translation of clinical science through effective medical communications to enhance patient care. Marcel is passionate about data-driven decision-making and building intelligence tools and models to better identify and engage the Medscape audience. All of this is to ensure more effective and impactful medical education and to provide more measurable program impact. Marcel holds an MBA with a concentration in statistics from Baruch College's Zicklin School of Business in New York, NY.

Dr Sheetal Patel leads the learning and behaviour change strategy at Amiculum, where she applies learning, behavioural and cognitive sciences to enhance audience experiences and deliver measurable outcomes at individual, team, and organisational levels.

With nearly 20 years of experience in medical communications, Sheetal has worked across medical education, healthcare marketing, patient engagement, and strategic planning — always with a single goal: driving meaningful change in audience behaviour. She has developed a behavioural strategy framework for organisational change, helping teams adopt impactful approaches to learning and engagement.

Sheetal began her career in medical research, earning a PhD in Gene Therapy, an MRes in Bioinformatics, and a BSc in Human Genetics, before moving into teaching and later transitioning into medical communications.

Her passion is using behavioural science and creative ideas to inspire learning, boost engagement, and drive lasting behaviour change in healthcare.

After 20 years at the world's biggest scientific publisher where Mike spent time carefully curating journal data, he's now spent 10 years on the outside, where he spends much of his time picking journals' reputations apart and using data science to reveal their hidden secrets. You can expect many anecdotes from the 'inside' from this "gamekeeper turned poacher". Mike's PhD is in Open Access publishing and altmetrics.

Helen is the Founder and CEO of One MSL, a specialist training provider and consultancy, with a specific focus on the Field Medical function. One MSL was built on a heritage of relevant industry experience: Novartis, Roche & Celgene and Helen’s tenure as Chair for the Medical Science Liaison Professional Association.

One MSL was created from a vision to drive standards of Field Medical excellence, and to maximise the ability of Field Medical colleagues to positively impact current and future patient outcomes through internal collaboration and external engagement.

One MSL is a trusted global solution provider. To date we have partnered with 40+ companies and trained more than 10 000 colleagues, across time zones and in multiple languages, through both live and virtual events.

One MSL is proud of its deep connections within the Field Medical community through LinkedIn (27K followers), surveys, webinars and podcasts.

Helen is motivated to make a difference within the evolving world of Medical Affairs. She is a consultant,  author, mentor, coach and trainer. She welcomes the opportunity to be a keynote speaker to inspire and reassure.  

Adam Baker is the vice president of revenue and enterprise excellence at Powtoon and advises large organizations on implementing & scaling AI transformation with a human-first approach.

Adam works mainly with highly regulated life science and pharma companies, helping Medical Affairs and Medical Information teams adopt AI responsibly by aligning innovation with governance for speed, scale and impact.